Pharma

Process development and GMP manufacturing of lactoperoxidase and glucose oxidase to support an IND filing and a Phase II clinical trial in the US.

Late‑stage results show divarasib superiority in KRAS G12C NSCLC, giredestrant preserves quality of life while improving efficacy, and Tam‑Peli shows robust activity in nasopharyngeal carcinoma.

Phase Ib shows 61% ORR at 8 mg/kg with manageable safety; data supported selection of 8 mg/kg for the ongoing global phase III EMBOLD SCLC‑301.

CHMP recommends talquetamab (TALVEY) with daratumumab ± pomalidomide for adults with relapsed/refractory multiple myeloma after ≥1 prior therapy, supported by MonumenTAL-3 efficacy and survival data.

More than 20 abstracts across lung, gynaecological and gastrointestinal cancers, including positive Ris‑Rez ES‑SCLC activity, Mo‑Rez durable responses in platinum‑resistant ovarian cancer, and Jemperli complete responses in MSI‑H rectal cancer.

A first‑in‑class IL‑6R inhibitor and the first and only at‑home subcutaneous treatment option for thyroid eye disease.

Approvals include Rasonque for metastatic pancreatic cancer, Foundayo oral GLP‑1 for weight and type 2 diabetes, Yuviwel for achondroplasia, two biosimilars and temozolomide for gliomas.

Oral orforglipron showed 5–11% weight loss at 72 weeks and 1.2–1.9 percentage‑point HbA1c reductions; CHMP opinion now goes to the European Commission for an EU licence.

First-in-class oral OX2R agonist now available; U.S. launch due next month pending DEA scheduling; Phase 3 showed significant improvements across NT1 symptoms with a consistent safety profile.

Randomized Phase II will test VVD-214 plus pembrolizumab versus pembrolizumab alone as first‑line treatment for advanced MSI‑high/dMMR colorectal cancer, enrolling ~140 patients.